Molecular landscape of osimertinib resistance in patients and patient-derived preclinical models

by Sun Min Lim, San-Duk Yang, Sangbin Lim, Seong Gu Heo, Stetson Daniel, Aleksandra Markovets, Rafati Minoo, Kyoung-Ho Pyo, Mi Ran Yun, Min Hee Hong, Hye Ryun Kim, Byoung Chul Cho
Published 2022-02-01

Checks and balance regulating lymphocyte cytokine production

by Stetson, Daniel B.
Published 2002

Prioritisation of structural variant calls in cancer genomes

by Ahdesmäki, Miika J., Chapman, Brad A., Cingolani, Pablo, Hofmann, Oliver, Sidoruk, Aleksandr, Lai, Zhongwu, Zakharov, Gennadii, Rodichenko, Mikhail, Alperovich, Mikhail, Jenkins, David, Carr, T. Hedley, Stetson, Daniel, Dougherty, Brian, Barrett, J. Carl, Johnson, Justin H.
Published 2017

Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer

by Ramalingam, Suresh S., Yang, James C. -H., Lee, Chee Khoon, Kurata, Takayasu, Kim, Dong-Wan, John, Thomas, Nogami, Naoyuki, Ohe, Yuichiro, Mann, Helen, Rukazenkov, Yuri, Ghiorghiu, Serban, Stetson, Daniel, Markovets, Aleksandra, Barrett, J. Carl, Thress, Kenneth S., Janne, Pasi A.
Published 2020

Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial.

by Schmid, Peter, Abraham, Jacinta, Chan, Stephen, Wheatley, Duncan, Brunt, Adrian Murray, Nemsadze, Gia, Baird, Richard D, Park, Yeon Hee, Hall, Peter S, Perren, Timothy, Stein, Robert C, Mangel, László, Ferrero, Jean-Marc, Phillips, Melissa, Conibear, John, Cortes, Javier, Foxley, Andrew, de Bruin, Elza C, McEwen, Robert, Stetson, Daniel, Dougherty, Brian, Sarker, Shah-Jalal, Prendergast, Aaron, McLaughlin-Callan, Max, Burgess, Matthew, Lawrence, Cheryl, Cartwright, Hayley, Mousa, Kelly, Turner, Nicholas C
Published 2020